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Abstract 
 
Polycystic ovary syndrome (PCOS) is one of 
the common forms of chronic anovulation 
associated with an increase in androgens. This 
disorder is associated with important 
morbidities during reproductive years. The 
objective of this research was to compare the 
effects of letrozole and routine treatment (oral 
Ethinylestradiol, cyproterone acetate and 
metformin) of polycystic ovary syndrome in 
improving symptoms of hyperandrogenism 
(hirsutism, acne). 
 
This is an applied-experimental study in which, 
80 patients diagnosed with PCOS (polycystic 
ovary syndrome) were randomly divided into 
two groups. The first group was treated with 2.5 
mg of Letrozole daily and the second group was 
treated with 500 mg of metformin once per day, 
100 mg of cyproterone acetate once per day 
since 5-15 days of menstruation and oral 
Ethinylestradiol daily since 5 -25 days of 
menstrual cycles and they were followed-up 
regularly and periodically in the endocrinology 
clinic. After collecting data, they were analyzed 
using spss Software. 
 
  Resumen  
 
El síndrome de ovario poliquístico (SOP) es 
una de las formas comunes de anovulación 
crónica asociada con un aumento de los 
andrógenos. Este trastorno se asocia con 
importantes morbilidades durante los años 
reproductivos. El objetivo de esta investigación 
fue comparar los efectos del letrozol y el 
tratamiento de rutina (etinilestradiol oral, 
acetato de ciproterona y metformina) del 
síndrome de ovario poliquístico para mejorar los 
síntomas de hiperandrogenismo (hirsutismo, 
acné). 
 
Este es un estudio experimental aplicado en el 
que 80 pacientes diagnosticados con SOP 
(síndrome de ovario poliquístico) se dividieron 
aleatoriamente en dos grupos. El primer grupo 
se trató con 2,5 mg de letrozol al día y el 
segundo grupo se trató con 500 mg de 
metformina una vez al día, 100 mg de acetato de 
ciproterona una vez al día desde los 5 a 15 días 
de menstruación y etinilestradiol oral 
diariamente de 5 a 25 días. de ciclos menstruales 
y fueron seguidos regularmente y 
periódicamente en la clínica de endocrinología. 
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No significant difference was found between 
two groups in the improvement of the hirsutism 
(p = 0.27). No significant difference was found 
between two groups in the improvement of acne 
(p = 0.54). In addition, the results of this study 
did not show any significant difference between 
the two groups in terms of acne and hirsutism 
improvement in the 6-month follow up. 
 
Based on the results of this study, two groups 
did not differ significantly. However, given the 
reduction in Ferriman-Gallwey score, letrozole 
can be a suitable drug for treating the symptoms 
of hyperandrogenism. Extensive studies are 
required in this regard to prove this assumption. 
 
Keyword: letrozole, polycystic ovary 
syndrome, metformin, cyproterone acetate, oral 
Ethinylestradiol 
 
 
 
Después de recopilar los datos, se analizaron 
utilizando el software 21 de spss. 
No se encontraron diferencias significativas 
entre los dos grupos en la mejora del hirsutismo 
(p = 0,27). No se encontraron diferencias 
significativas entre los dos grupos en la mejora 
del acné (p = 0.54). Además, los resultados de 
este estudio no mostraron diferencias 
significativas entre los dos grupos en cuanto a la 
mejoría del acné y el hirsutismo en el 
seguimiento de 6 meses. 
 
Sobre la base de los resultados de este estudio, 
dos grupos no difirieron significativamente. Sin 
embargo, dada la reducción en la puntuación de 
Ferriman-Gallwey, el letrozol puede ser un 
fármaco adecuado para tratar los síntomas de 
hiperandrogenismo. Se requieren estudios 
extensos a este respecto para probar este 
supuesto. 
 
Palabra clave: letrozol, síndrome de ovario 
poliquístico, metformina, acetato de 
ciproterona, etinilestradiol oral 
 
Resumo
 
A síndrome do ovário policístico (SOP) é uma das formas mais comuns de anovulação crônica associada 
a um aumento de andrógenos. Este distúrbio está associado a importantes morbidades durante os anos 
reprodutivos. O objetivo desta pesquisa foi comparar os efeitos do tratamento com letrozol e rotina 
(Etinilestradiol oral, acetato de ciproterona e metformina) da síndrome dos ovários policísticos na melhora 
dos sintomas de hiperandrogenismo (hirsutismo, acne). 
 
Este é um estudo experimental-aplicado no qual 80 pacientes diagnosticados com SOP (síndrome do 
ovário policístico) foram divididos aleatoriamente em dois grupos. O primeiro grupo foi tratado com 2,5 
mg de Letrozole diariamente e o segundo grupo foi tratado com 500 mg de metformina uma vez por dia, 
100 mg de acetato de ciproterona uma vez por dia desde 5-15 dias da menstruação e Etinilestradiol oral 
diariamente desde 5 -25 dias de ciclos menstruais e eles foram acompanhados regularmente e 
periodicamente na clínica de endocrinologia. Depois de coletar os dados, eles foram analisados usando o 
spss 21Software. 
 
Nenhuma diferença significativa foi encontrada entre os dois grupos na melhora do hirsutismo (p = 0,27). 
Nenhuma diferença significativa foi encontrada entre os dois grupos na melhora da acne (p = 0,54). Além 
disso, os resultados deste estudo não mostraram diferença significativa entre os dois grupos em termos de 
melhora da acne e do hirsutismo no seguimento de 6 meses. 
 
Com base nos resultados deste estudo, dois grupos não diferiram significativamente. No entanto, dada a 
redução no escore de Ferriman-Gallwey, o letrozol pode ser um medicamento adequado para tratar os 
sintomas do hiperandrogenismo. Estudos extensos são necessários a esse respeito para provar essa 
suposição. 
 
Palavras-chave: letrozol, síndrome dos ovários policísticos, metformina, acetato de ciproterona, 
Etinilestradiol oral 
 
Introduction 
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Polycystic ovary syndrome (PCOS) is an 
endocrine, metabolic and systemic reproduction 
disease. It is very common and affects 6-8% of 
women in their reproductive age (Lee et al., 
2018; Sylus et al., 2018).  Patients with PCOS are 
usually women who are at their reproductive age 
(Lee et al., 2018). A study conducted in India 
reported that the prevalence of PCOS in young 
girls aged 15 to 24 was 22.5% (Joshi et al., 2014). 
PCOS is associated with the clinical conditions of 
increased androgen. Increased androgen is 
responsible for these clinical signs and 
complications of this syndrome. One of these 
conditions is hirsutism (Longo et al., 2012). 
Hirsutism involves excessive hair growth as a 
male pattern and affects about 10% of women 
(Farr et al., 2010).  Excessive increase in 
androgens in women leads to increased hair 
growth in most androgen-sensitive areas. 
However, it is followed by an increase in hair loss 
in the head area. Important points in evaluation 
of hirsutism include the onset age and the speed 
of progression and associated symptoms, such as 
acne (Boivin et al., 2007). A simple and common 
method to grade the hirsutism is to use 
Ferriman-Gallwey scale. In this grading, nine 
areas of the body are examined in terms of 
hirsutism and score of 1 to 4 is given to each area. 
A total of higher than 8 indicates overgrowth due 
to androgens (Balasubramanian et al., 2010). 
Hyperandrogenism is a key factor in PCOS. After 
activating the activity of the aromatase enzyme, 
androgen is accumulated, leading to endocrine 
imbalance. Letrozole is a non-steroidal 
aromatase inhibitor. It contributes to androgen 
non-accumulation and prevention of 
hyperandrogenism (Daneasa et al., 2016). 
Chronic infection and infertility are considered 
among the most common complications of 
PCOS (Duleba & Dokras, 2012).  
 
It has been reported that patients with PCOS 
are hospitalized twice more than to healthy 
subjects (Hart & Doherty, 2015). Thus, accurate 
and early diagnosis of PCOS and effective 
therapies on it seems to be necessary to reduce 
costs and improve the function (Kamangar et al., 
2015). Nitrogen oxide (NO) indicates 
endothelial function, increases naturally during 
ovarian folliculogenesis and it contributes in 
maintaining the pregnancy. Previous studies 
reported that NO level decreases in infertile 
women with PCOS (Mahran et al., 2016).  As 
letrozole is widely used nowadays to treat 
infertility and as it has been approved by the FDA 
for the treatment of breast cancer and its long-
term use in women with breast cancer and 
women with infertility caused by Polycystic ovary 
syndrome has not been associated with 
important complications (Craigle, 2007), the 
objective of this study is to compare the effects 
of common and routine treatments (combination 
of oral Ethinylestradiol, cyproterone acetate and 
metformin) and modern treatments through 
letrozole aromatase inhibitor. 
 
Methodology  
 
This study is an applied-experimental study in 
which 80 patients diagnosed with PCOS 
(Polycystic ovary syndrome) were randomly 
divided into two groups based on Roterrandom 
criteria. One number was assigned for each 
person diagnosed with PCOS and the patients 
were assigned into case and control groups 
alternately.  The first group was treated with 2.5 
mg of Letrozole daily and the second group was 
treated with 500 mg of metformin once per day, 
100 mg of cyproterone acetate once per day 
since 5-15 days of menstruation and oral 
Ethinylestradiol daily since 5 -25 days of 
menstrual cycles and they were followed-up 
regularly and periodically in the endocrinology 
clinic and the information derived from 
improvement or non-improvement of the 
symptoms was carefully and separately recorded 
by one person for each case. At the end of a 6-
month period, data were analyzed. Exclusion 
criteria included kidney failure, metabolic 
acidosis, and history of thromboembolic disease, 
liver disorders, liver tumors, meningioma, severe 
and chronic depression, history of 
thromboembolic disease, pregnancy, and 
breastfeeding. After data collection, they were 
analyzed using spss 21 software. 
 
Results  
 
In this research, 80 women at their 
reproductive age (between 18 and 38) with 
polycystic ovary syndrome who admitted to 
Endocrinology clinic of Imam Khomeini Hospital 
in Urmia due to symptoms of hyperandrogenism 
(hirsutism, acne) were studied. These patients 
were divided into two groups (each contained 40 
patients). Among all patients studied, 4 patients 
were finally excluded from the study due to lack 
of meeting the inclusion criteria and the study 
continued with 76 patients. The mean age of 
patients was 28.47 ± 6.06 years in the control 
group and 27.29 ± 5.60 years in the case group. 
The mean BMI was 27.29 ± 2.83 kg / m2 in the 
control group and 25.91 ±3.84 kg / m2 in the 
case group. Based on the T-test, no significant 
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difference was found between age and BMI of 
the two groups. Comparing the hirsutism 
improvement in the two groups showed that the 
baseline mean Ferriman-Gallwey score was 
20.80 ± 2.69 in the control group and 20.80± 
3.33 in the case group, which no significant 
difference was not found between the two 
groups in Ferriman-Gallwey scores based on the 
T-test, when they referred to clinic (p=0.27). 
 
After follow up of patients for 6 months, the 
mean Ferriman-Gallwey score was 16.32 ± 2.83 
in the control group and 16.44± 2.75 in the case 
group. Based on the T – TEST, no significant 
difference was found between two groups in the 
Ferriman-Gallwey scores after the treatment and 
during the follow up period. In the study of acne 
improvement, the results showed that in 40 
patients in the control group, acne improved 
significantly in 24 patients (60%) and it improved 
partially in 16 (40%) patients. In case group, out 
of 36 patients, acne improved significantly in 24 
patients (66.7%), while improvement was partial 
in 12 patients (33.3%). Based on the Chi-square 
test, there was no significant difference between 
the two groups in terms of acne improvement 
during the second visit (P=0.54) (Table 1). 
 
Table 1: Distribution of absolute and relative acne improvement in second visit of patients  
 
Group   Acne improvement in second visit (after two months) 
Total   
 improvement  
Non-improvement or partial 
improvement  
Control   24(60)% 16(40 )% 40 (100 )% 
Case 24 (66.7)% 12 (33.3 )% 36(100)% 
 Total   48 (63.2)% 28(368)% 76 (100 )% 
p.value Chi-  exact test=  0. 54 
 
In 6-month follow, out of 40 patients in the control group, 30 patients (75%) showed significant acne 
improvement and 10 patients (25%) had partial improvement. Out of the 36 patients in the case group, 32 
patients (88.9%) showed significant acne improvement and 4 patients (11.1%) showed partial 
improvement. Based on Chi-square test, no significant difference was found between the two groups and 
acne improvement in 6-month follow up (P = 0.11) (Table 2). 
 
Table 2: absolute and relative distribution of acne improvement in 6-month follow up patients studied 
 
Group  Acne improvement status  
Total   
 improvement   
Non-improvement or 
partial improvement  
control  30(75)% 10(25)% 40 (100 )% 
Case 32 (88.9)% 4 (11.1 )% 36(100)% 
 Total   62 (81.6)% 14 (18.4 )% 76 (100 )% 
p.value Chi- square=  0. 11 
 
Dissuasion  
 
Ovulation disorders are common causes of 
infertility and Polycystic ovary syndrome (PCOS) 
is an endocrine disorder affecting women in their 
reproductive age (Mehdinejadiani et al., 2018). 
The prevalence of PCOS varies in different 
populations and its prevalence has been reported 
to be between 5% and 15% according to 
phenotype and ethnicity (Bozdag et al., 2016). It 
has been well recognized that steroid hormones 
have a good effect on endometrial proliferation 
and folliculogenesis in ovarian of the fertile 
women (Gifford, 2015). Letrozole is a non-
steroidal aromatase inhibitor with a short half-
life. It is among the drug used widely in the 
treatment of infertility and it is used as ovulation-
inducing drug, especially in patients with PCOS 
(Mehdinejadiani et al., 2018; Franik et al., 2015). 
The present study was conducted to compare 
the effects of two different treatments on PCOS. 
Combination of oral Ethinylestradiol, 
cyproterone acetate and metformin was used in 
the first treatment, while letrozole aromatase 
inhibitor was used in the second treatment. 
 
Comparing the hirsutism improvement of 
patients of two groups showed that the mean 
Ferriman-Gallwey score at the time of admission 
to clinic was 20.05 ± 2.69 in the control group 
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and 20.80± 3.33 in the case group. These results 
suggest lack of difference between two drugs 
used by patients in terms of Ferriman-Gallwey 
score when patients admitted to the clinic. The 
results revealed that Ferriman-Gallwey score 
decreased to 16.32 ± 2.83 in the control group 
subjects and it decreased to 16.44 2.75 in 
patients treated with the aromatase letrozole 
inhibitor after 6 months of follow-up. Although 
no significant difference was seen in this study, 
the Ferriman-Gallwey score was significantly 
reduced compared to combined treatment. With 
regard to acne improvement, the results of our 
study showed that letrozole aromatase inhibitor 
had a better effect than combined treatment. In 
studies conducted by Saha et al. (2012), Atay et 
al. (2006) Roy et al. (2012), letrozole had better 
effect on fertility than clomiphene citrate. These 
results are in line with the results of our study 
with regard to the effect of letrozole (Although 
we did not examine the fertility of women, but 
we observed the effect of letrozole on inducing 
fertility and improvement of acne and hirsutism 
according to the results).  
 
In another study conducted by Mehdinejadiani 
et al (2018), it was reported that the use of 
letrozole compared to clomiphene citrate had a 
better effect on the mean of estrogen and 
progesterone, an increase in the appropriate 
endometrial protein and a more acceptable 
activation of the Wnt / B- catenin pathway. In a 
systematic study conducted by Escobar et al. 
(2012) on hirsutism, their results focused on 
epidemiology, pathology, diagnosis and 
treatment of hirsutism. Their study on the 
relationship between androgens and hair growth 
revealed that growth of hair in the sexual areas 
was clearly associated with androgenic 
hormones.  The results of the study carried out 
by Escobar et al. (2012) and the results of our 
study on the effects of letrozole in comparison 
with effects of conventional treatment, no 
significant relationship was found, but acne and 
hirsutism improved significantly after treatment. 
Our study proves that due to objective and 
double-blind evaluations of the effects of 
treatment, small size of available samples, short 
duration of interventional studies and specific 
physiology of hair growth, each person's 
response to treatment may vary. There is also 
limitation in scoring system on the comparative 
investigation of the effects of various existing 
treatments. The only side effects observed in this 
study included dizziness and nausea. 
 
Conclusion 
 
Based on the research results, it seems that 
letrozole to be suitable drug for the treatment of 
symptoms of hyperandrogenism. However, 
extensive studies are required to prove this 
assumption . 
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